Dokument: Advances and Challenges in KRAS Mutation Detection and Clinical Implications

Titel:Advances and Challenges in KRAS Mutation Detection and Clinical Implications
URL für Lesezeichen:https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=73615
URN (NBN):urn:nbn:de:hbz:061-20260615-142711-0
Kollektion:Publikationen
Sprache:Englisch
Dokumententyp:Wissenschaftliche Texte » Artikel, Aufsatz
Medientyp:Text
Autoren: Ahmadian, Mohammad Reza [Autor]
Mirlohi, Maryam Sadat [Autor]
Yousefi, Tooba [Autor]
Razaviyan, Javad [Autor]
Nomiri, Samira [Autor]
Pishbin, Esmail [Autor]
Shabani-Rad, Meer-Taher [Autor]
Salami, Siamak [Autor]
Dateien:
[Dateien anzeigen]Adobe PDF
[Details]1,53 MB in einer Datei
[ZIP-Datei erzeugen]
Dateien vom 15.06.2026 / geändert 15.06.2026
Stichwörter:oncogene , KRAS mutations , molecular method , targeted therapy , precision medicine
Beschreibung:Aberrant activation of the RAS signaling pathway is a halmark of various cancers. This activation, is often caused by mutations in RAS genes or other pathway components and, drivesi uncontrolled cell growth and proliferation. Studies have demonstrated that certain codon mutations can significantly influence the clinical outcomes of cancer patients. Historically, KRAS was considered “undruggable”; however, recent advancements in drug discovery have led to the development of promising KRAS inhibitors. Accurately identifying the specific type of KRAS mutation in a patient is essential for making optimal treatment decisions. Several methods have been developed for detecting KRAS mutations to address this need, focusing on creating robust, rapid, sensitive, accurate, and cost-effective approaches, particularly for point-of-care applications. Starting with the Ras family and RASopathies, this review provides a comprehensive overview of KRAS mutation detection methods, ranging from research-use-only techniques to in vitro diagnostic-certified tests. Published results are critically evaluated in terms of accuracy, sensitivity, cost, throughput, and suitability for various sample types and clinical settings. This, offers researchers and clinicians an up-to-date resource for.
Rechtliche Vermerke:Originalveröffentlichung:
Mirlohi, M. S., Yousefi, T., Razaviyan, J., Nomiri, S., Pishbin, E., Shabani-Rad, M.-T., Ahmadian, M. R., & Salami, S. (2025). Advances and Challenges in KRAS Mutation Detection and Clinical Implications. Cancers, 18(1), Article 31. https://doi.org/10.3390/cancers18010031
Lizenz:Creative Commons Lizenzvertrag
Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz
Fachbereich / Einrichtung:Medizinische Fakultät
Dokument erstellt am:15.06.2026
Dateien geändert am:15.06.2026
english
Benutzer
Status: Gast
Aktionen